RT Journal Article
SR Electronic
T1 Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.12.21261929
DO 10.1101/2021.08.12.21261929
A1 Silvia Stringhini
A1 María-Eugenia Zaballa
A1 Nick Pullen
A1 Javier Perez-Saez
A1 Carlos de Mestral
A1 Andrea Loizeau
A1 Julien Lamour
A1 Francesco Pennacchio
A1 Ania Wisniak
A1 Roxane Dumont
A1 Hélène Baysson
A1 Viviane Richard
A1 Elsa Lorthe
A1 Claire Semaani
A1 Jean-François Balavoine
A1 Didier Pittet
A1 Nicolas Vuilleumier
A1 François Chappuis
A1 Omar Kherad
A1 Andrew S. Azman
A1 Klara Posfay-Barbe
A1 Laurent Kaiser
A1 Idris Guessous
A1 the Specchio-COVID19 study group
YR 2021
UL http://medrxiv.org/content/early/2021/08/13/2021.08.12.21261929.abstract
AB Background Up-to-date seroprevalence estimates are critical to describe the SARS-CoV-2 immune landscape in the population and guide public health measures. We aimed to estimate the seroprevalence of anti-SARS-CoV-2 antibodies 15 months into the COVID-19 pandemic and six months into the vaccination campaign.Methods We conducted a population-based cross-sectional serosurvey between June 1 and July 7, 2021, recruiting participants from age- and sex-stratified random samples of the general population. We tested participants for anti-SARS-CoV-2 antibodies targeting the spike (S) or nucleocapsid (N) proteins (Roche Elecsys immunoassays). We estimated the anti-SARS-CoV-2 antibodies seroprevalence following vaccination and/or infection (anti-S antibodies), or infection only (anti-N antibodies).Results We included 3355 individuals, of which 1814 (54.1%) were women, 697 (20.8%) were aged <18 years and 449 (13.4%) were aged ≥65 years, 2161 (64.4%) tested positive for anti-S antibodies, and 906 (27.0%) tested positive for anti-N antibodies. The total seroprevalence of anti-SARS-CoV-2 antibodies was 66.1% (95% credible interval, 64.1-68.0). We estimated that 29.9% (28.0-31.9) of the population developed antibodies after infection; the rest having developed antibodies only via vaccination. Seroprevalence estimates were similar across sexes, but differed markedly across age groups, being lowest among children aged 0-5 years (20.8% [15.5-26.7]) and highest among older adults aged ≥75 years (93.1% [89.6-96.0]). Seroprevalence of antibodies developed via infection and/or vaccination was higher among participants with a higher educational level.Conclusions Most adults have developed anti-SARS-CoV-2 antibodies, while most teenagers and children remain vulnerable to infection. As the SARS-CoV-2 Delta variant spreads and vaccination rates stagnate, efforts are needed to address vaccine hesitancy, particularly among younger individuals and socioeconomically disadvantaged groups, and to minimize spread among children.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Swiss Federal Office of Public Health, the General Directorate of Health of the Department of Safety, Employment and Health of the canton of Geneva, the Private Foundation of the Geneva University Hospitals, the Swiss School of Public Health (Corona Immunitas Research Program) and the Fondation des Grangettes. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. SS and GP had access to all the data in the study and SS had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Geneva Cantonal Commission for Research Ethics (Project Number 2020-00881).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be made available upon submission of a data request application to the corresponding author. Virologically-confirmed SARS-CoV-2 infection data are available from the Canton of Geneva: https://infocovid.smc.unige.ch/. Biological material can be reused for further studies upon approval by the cantonal ethics commission of the state of Geneva.